erythropoiesis

Epoetin zeta, a derivative of the endogenous protein erythropoietin, functions as an erythropoiesis-stimulating agent. It is utilized to investigate symptomatic anemia associated with renal disorders, referred to as symptomatic renal anemia [1].

Epoetin beta (rhEPO), a recombinant erythropoietin, is crucial for sustaining erythropoiesis and is utilized in anemia research [1].

Vadadustat is a novel, titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia.

Roxadustat-d5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg/kg. Roxadustat reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5/6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......

Sotatercept (ACE-011), a soluble activin receptor type IIA (ACVR2A) IgG Fc fusion protein, aims to rebalance growth-promoting and inhibiting signaling pathways by targeting activin and growth differentiation factors. This compound shows potential in treating pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, and multiple myeloma (MM) osteolytic lesions [1] [2] [3] [4] [5].

Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia.

3-(3,4-Dimethoxyphenyl)propanoic acid (3,4-Dimethoxyhydrocinnamic acid) is an orally active short-chain fatty acid (SCFAs). It promotes γ-globin gene expression and erythropoiesis in vivo and can be used in beta hemoglobinopathies and other anemias.

Mitapivat (PKR-IN-1), also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.

Roxadustat-13C-15N is 13C and 15N labeled Roxadustat.

Roxadustat-13C2-15N is 13C and 15N labeled Roxadustat.

Roxadustat (FG-4592) is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with potential anti-anemic activity.